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Abstract: (1) Background: Markers identifying which patients with metastatic, castration-resistant
prostate cancer (mCRPC) will benefit from cabazitaxel therapy are currently lacking. Therefore, the
aim of this study was to identify markers associated with outcome to cabazitaxel therapy based on
counts and gene expression profiles of circulating tumor cells (CTCs). (2) Methods: From 120 mCRPC
patients, CellSearch enriched CTCs were obtained at baseline and after 6 weeks of cabazitaxel therapy.
Furthermore, 91 genes associated with prostate cancer were measured in mRNA of these CTCs.
(3) Results: In 114 mCRPC patients with an evaluable CTC count, the CTC count was independently
associated with poor progression-free survival (PFS) and overall survival (OS) in multivariable
analysis with other commonly used variables associated with outcome in mCRPC (age, prostate
specific antigen (PSA), alkaline phosphatase, lactate dehydrogenase (LDH), albumin, hemoglobin),
together with alkaline phosphatase and hemoglobin. A five-gene expression profile was generated
to predict for outcome to cabazitaxel therapy. However, even though this signature was associated
with OS in univariate analysis, this was not the case in the multivariate analysis for OS nor for
PFS. (4) Conclusion: The established five-gene expression profile in CTCs was not independently
associated with PFS nor OS. However, along with alkaline phosphatase and hemoglobin, CTC-count
is independently associated with PFS and OS in mCRPC patients who are treated with cabazitaxel.
Keywords: mCRPC; prostate cancer; circulating tumor cells; CTCs; biomarker
1. Introduction
The number of treatment options for metastatic castration-resistant prostate cancer (mCRPC)
have increased rapidly in the last decade. Multiple treatment options are now available for mCRPC
patients, including the chemotherapeutic agents docetaxel and cabazitaxel, the endocrine therapies
abiraterone and enzalutamide, and options such as Radium-223 [1–7]. Therefore, biomarkers able to
predict outcome to a particular treatment are necessary to select the right drug for the right patient at
the right time. As the optimal treatment sequencing is currently unclear, one of the agents that would
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benefit from biomarkers for predicting which patients will benefit from that therapy is cabazitaxel,
which is commonly given after progression to docetaxel in mCRPC patients.
The enumeration and characterization of circulating tumor cells (CTCs) hold great promise as
predictive biomarkers for guiding optimal treatment sequencing. CTCs are cells that are shed from the
tumor and/or metastatic lesions and can be isolated from the peripheral blood. In prostate cancer, the
enumeration of CTCs is a strong independent prognostic factor for progression-free survival (PFS) and
overall survival (OS) both before and during therapy, as shown in multiple studies [8–11]. However,
the prognostic value for patients treated with cabazitaxel has only been analyzed in a small series of
56 patients [12].
Besides the enumeration of CTCs, characterization of these CTCs can help in predicting therapy
response. One of the biomarkers that may carry predictive value is the androgen receptor (AR) splice
variant 7 (AR-V7). Prior research has shown that AR-V7-positive patients benefit less from endocrine
treatment than those who are AR-V7-negative [13], but that the AR-V7 status does not influence
response to chemotherapy [14,15].
The advantage of CTCs is that they can be obtained in a minimally-invasive manner and mRNA
of these cells can be isolated and analyzed. Therefore, gene expression profiles containing multiple
genes can be measured in CTCs, which might be helpful in predicting outcome to therapies.
Here, we aimed to identify markers associated with outcome to cabazitaxel therapy. To this end,
we enumerated CTCs to confirm the prognostic value of CTC counts in mCRPC patients treated with
cabazitaxel. Furthermore, we aimed to identify a gene expression profile determined in CTCs that is
associated with outcome in mCRPC patients treated with cabazitaxel therapy.
2. Results
2.1. Patient Characteristics
As shown in Table 1, the median age of all 120 evaluable patients was 69 years (range 49–82 years).
Only patients with a WHO performance score of 0 or 1 were included in the study. All patients had been
previously treated with docetaxel. Only one patient received another line of chemotherapy besides
docetaxel in a trial. In total, 36% of the patients had received anti-AR treatment (mainly abiraterone
23/43, 53%) for mCRPC before enrollment. Of the 114 patients with a known baseline CTC enumeration,
42 received anti-AR therapy and 72 did not. Of the patients who received anti-AR therapy, 14 (33%)
patients had < 5 CTCs and 28 (67%) had ≥ 5 CTCs. In the 72 patients without endocrine pretreatment,
23 (32%) had < 5 CTCs and 49 (68%) had ≥ 5 CTCs (p = 1.00).
2.2. Circulating Tumor Cells at Baseline
In six of the 120 patients a baseline CTC enumeration could not be performed—three patients
missed the baseline blood draw for enumeration and characterization of CTCs, one patient only missed
the baseline blood draw for enumeration of CTCs, and two patients did not have enough blood
in the CellSave tube to perform a reliable CTC enumeration. Therefore, in 114 patients a baseline
CTC enumeration was performed. The median baseline CTC count was 15.5 (range 0–1025). In total,
37 patients had < 5 CTCs at baseline and the remaining 77 had ≥ 5 CTCs. When looking at the patient
characteristics, only WHO performance status, LDH and alkaline phosphatase were significantly
different between the patients with < 5 and ≥ 5 CTCs (p = 0.045, p = 0.001 and p < 0.001, respectively)
(see Table 1).
Patients with <5 CTCs before start of cabazitaxel therapy had a significantly better PFS and OS
as compared to patients with ≥ 5 CTCs at baseline (both p < 0.001) (Figure 1). The median PFS in
the entire cohort was 5.3 months. Patients with < 5 CTCs had a median PFS of 8.0 months, while
this was 4.4 months for patients with ≥ 5 CTCs (p < 0.001). The median OS was 11.8 months in all
patients (n = 114), 18.9 months in the patients with < 5 CTCs, and 7.9 months for patients with ≥ 5
CTCs (p < 0.001).
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Table 1. Patient characteristics.
Category N % < 5 CTC ≥ 5 CTC p-Value
Age 0.968
< 65 years 31 26 10 19
≥ 65 years 89 74 27 58
WHO performance score 0.045
0 61 51 24 33
1 59 49 13 44
Type of castration 1.000
Surgical 15 13 5 10
LHRH agonist 105 88 32 67
Prior chemotherapy lines
1 (only docetaxel) 119 99 37 76
2 1 1 0 1
Prior antiandrogen therapy for mCRPC * 0.326
Abiraterone 23 19 10 12
Enzalutamide 9 8 2 7
Orteronel 12 10 3 9
None 77 64 23 49
Baseline chemistry Median Range Median (range) Median (range)
LDH U/L (n = 118) 312 141–1843 237.5 (151–531) 353 (141–1843) 0.001
ALP U/L (n = 119) 128 39–909 105 (43–409) 174 (39–909) <0.001
PSA µg/L (n = 120) 152 4.5–5300 120 (45–2000) 175 (7–5300) 0.519
CTC count (n = 114) 15.5 0–1025 1 (0–4) 51 (5–1025)
Patients characteristics of the 120 patients included in this study. Note: CTC = circulating tumor cells, LHRH
agonist = luteinizing hormone-releasing hormone agonist; mCRPC = metastatic castration-resistant prostate cancer;
ALP = alkaline phosphatase; LDH = lactate dehydrogenase; PSA = prostate specific antigen. * One patient received
enzalutamide and orteronel sequentially. CTC counts are from baseline CTC enumeration.
Figure 1. Cont.
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Figure 1. PFS and OS in relation to dichotomized CTC count at baseline. Kaplan Meier curves of (A)
progression-free survival (PFS) and (B) overall survival (OS) in relation to circulating tumor cell (CTC)
count at baseline. CTC counts are divided into two categories of < 5 CTCs and ≥ 5 CTCs.
2.3. Circulating Tumor Cell Dynamics at Baseline and Follow-Up
A matched baseline and follow-up (at 6 weeks) CTC enumeration was available for 95 patients.
These patients were divided into four groups: group 1 contained patients with < 5 CTCs at baseline
who remained < 5 CTCs during follow-up (n = 24); group 2 had ≥ 5 CTCs at baseline but had < 5 CTCs
during therapy (n = 19); group 3 had < 5 CTCs at baseline and ≥ 5 CTCs during therapy (n = 5); and
group 4 were patients who had ≥ 5 CTCs both at baseline and during therapy (n = 47).
Median PFS for group 1 was 8.7 months, while it was 6.4 months for group 2, 7.4 months for
group 3, and 3.5 months for group 4. There was a significant difference between group 4 and group 1
(p < 0.001), group 2 (p < 0.001), and group 3 (p = 0.032). Between the other groups, no significant
difference was found. Median OS for group 1 was 19.0 months, while it was 12.8 months for group
2, 23.0 months for group 3, and 6.9 months for group 4. For OS, there was also a difference between
group 4 and group 1 (p < 0.001), group 2 (p = 0.003), and group 3 (p = 0.003). Also, a difference between
group 1 and 2 was found (p = 0.016). In Figure 2, a Kaplan–Meier plot for PFS and OS of the different
groups of patients is shown.
2.4. Gene Expression Profiles of CTC-Specific Genes
To evaluate the predictive value of gene expression levels for therapy outcome for patients treated
with cabazitaxel, 91 genes were measured (see Supplementary Table S1a). Of these genes, 34 had a
significantly higher expression in CTC samples compared to samples from healthy blood donors (HBDs)
(with a false discovery rate (FDR) of 5%). These genes are listed in Supplementary Table S1b. Hierarchical
clustering of the 34 CTC-specific genes in all baseline samples with available gene expression data
(n = 63) divided the samples into two groups (Supplementary Figure S1). The median CTC count in
the first group was 19, while this was 154 in the second group (p < 0.001). However, when these two
subgroups were visualized in a Kaplan–Meier plot for PFS and OS and tested with the Log-Rank test,
there was no difference in PFS or OS between the groups (see Supplementary Figure S2).
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Figure 2. PFS and OS in relation to CTC groups. Kaplan Meier curves of (A) progression-free survival
(PFS) and (B) overall survival (OS) in relation to circulating tumor cell (CTC) count. CTC counts are
divided into four categories: (1) <5 CTCs at baseline and <5 CTCs during treatment, (2) ≥5 CTCs at
baseline and <5 CTCs during treatment, (3) <5 CTCs at baseline and ≥5 CTCs during treatment and (4)
≥5 CTCs at baseline and ≥5 CTCs during treatment.
2.5. Gene Expression Profiles in Relation to Outcome to Cabazitaxel Therapy
The 34 CTC-specific genes were also analyzed to determine a gene expression panel that predicts
outcome to cabazitaxel therapy. In the 63 baseline samples, five genes were identified with the highest
discriminatory power to predict PFS on cabazitaxel therapy. These genes were AGR2, FOXA1, DKK1,
FAT1 and TMPRSS2. These were also the genes that were significantly associated with prolonged PFS
in univariate Cox regression analysis (see Supplementary Table S2). The patients were divided into
two groups using a median split of the predicted risk score, with 32 patients having a high predicted
risk score and 31 patients having a low predicted risk score. However, these groups did not show
statistically different survival curves for PFS (p = 0.27). When we used this estimated risk score for OS,
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there was a difference in outcome between the high and low risk groups (p = 0.039). Supplementary
Figure S3 shows the Kaplan Meier curves of both PFS and OS in relation to the high and low risk groups.
2.6. Cox Regression Analysis
As the primary objective of this study was to identify the most powerful markers for outcome
to cabazitaxel therapy, all available variables (baseline CTC count, age, PSA, alkaline phosphatase,
lactate dehydrogenase (LDH), albumin, hemoglobin and the 5-gene profile) were analyzed in uni- and
multivariate Cox regression models for both PFS and OS in the 63 patients for which all of these data
were available. For PFS, univariate Cox regression analyses showed a significant association with both
CTC count and hemoglobin. In multivariate regression analysis, both CTC count (HR 1.001, 95% CI
1.00–1.00, p = 0.023) and hemoglobin (HR 0.731, 95% CI 0.56–0.95, p = 0.020) remained independent
prognostic factors for PFS (see Table 2A). For OS, five variables were significant in univariate Cox
Regression analysis: the 5-gene profile, CTC count, alkaline phosphatase, LDH and hemoglobin.
In multivariate analysis, only CTC count (HR 1.002, 95% CI 1.00–1.00, p = 0.009) and hemoglobin
(HR 0.642, 95% CI 0.48–0.85, p = 0.002) remained significant independent factors for OS (see Table 2B).
Table 2. Cox Regression analysis (n = 63).
(A) Univariate Analysis Multivariate Analysis
Variable HR 95% CI p-Value HR 95% CI p-Value
5-gene profile 1.325 0.80–2.20 0.279
CTC count 1.001 1.00–1.00 0.011 1.001 1.00–1.00 0.023
Age 0.988 0.95–1.02 0.508
PSA 1.000 1.00–1.00 0.777
ALP 1.001 1.00–1.00 0.101
LDH 1.000 0.99–1.00 0.248
Albumin 0.954 0.91–1.00 0.070
Hemoglobin 0.709 0.54–0.93 0.011 0.731 0.56–0.95 0.020
(B) Univariate Analysis Multivariate Analysis
Variable HR 95% CI p-Value HR 95%CI p-Value
5-gene profile 1.743 1.02–2.98 0.042
CTC count 1.002 1.00–1.00 0.006 1.002 1.00–1.00 0.009
Age 1.015 0.98–1.05 0.418
PSA 1.000 1.00–1.00 0.090
ALP 1.001 1.00–1.00 0.038
LDH 1.001 1.00–1.00 0.006
Albumin 0.949 0.90–1.00 0.056
Hemoglobin 0.631 0.48–0.84 0.002 0.642 0.48–0.85 0.002
Cox regression analysis in 63 patients with baseline gene expression data available for (A) progression-free survival
and (B) overall survival. The 5-gene profile was dichotomized to high and low predicted risk, while the other
variables are continuous. Note: ALP = alkaline phosphatase; HR = hazard ratio; LDH = lactate dehydrogenase;
PSA = prostate specific antigen. CTC counts are from baseline CTC enumeration.
When looking at the baseline variables without the 5-gene expression profile, 114 patients had
all of these data available. Baseline CTC count, alkaline phosphatase, LDH and hemoglobin were
significant in univariate analysis for PFS. In multivariate analysis, CTC count (HR 1.002, 95% CI
1.00–1.00, p < 0.001), alkaline phosphatase (HR 1.002, 95% CI 1.00–1.00, p = 0.014), and hemoglobin
(HR 0.749, 95% CI 0.61–0.92, p = 0.005) remained independent prognostic factors for PFS (see Table 3A).
For OS, CTC count, alkaline phosphatase, LDH, albumin and hemoglobin were significant in univariate
analysis. In multivariate analysis, only CTC count (HR 1.002, 95% CI 1.00–1.00, p < 0.001), alkaline
phosphatase (HR 1.002, 95% CI 1.00–1.00, p = 0.006), and hemoglobin (HR 0.591, 95% CI 0.47–0.74,
p < 0.001) remained independent prognostic factors (see Table 3B).
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Table 3. Cox Regression analysis (n = 114).
(A) Univariate Analysis Multivariate Analysis
Variable HR 95% CI p-Value HR 95%CI p-Value
CTC count 1.002 1.00–1.00 <0.001 1.002 1.00–1.00 <0.001
Age 0.989 0.96–1.02 0.453
PSA 1.000 1.00–1.00 0.732
ALP 1.002 1.00–1.00 <0.001 1.002 1.00–1.00 0.014
LDH 1.001 1.00–1.00 0.007
Albumin 0.983 0.94–1.03 0.490
Hemoglobin 0.694 0.57–0.85 <0.001 0.749 0.61–0.92 0.005
(B) Univariate Analysis Multivariate Analysis
Variable HR 95% CI p-Value HR 95%CI p-Value
CTC count 1.003 1.00–1.00 <0.001 1.002 1.00–1.00 <0.001
Age 1.017 0.99–1.05 0.276
PSA 1.000 1.00–1.00 0.112
ALP 1.002 1.00–1.00 <0.001 1.002 1.00–1.00 0.006
LDH 1.002 1.00–1.00 <0.001
Albumin 0.952 0.91–0.99 0.044
Hemoglobin 0.551 0.44–0.68 <0.001 0.591 0.47–0.74 <0.001
Cox regression analysis in 114 patients with baseline CTC enumeration available for (A) progression-free survival
and (B) overall survival. All variables are continuous in this regression analysis. Note: ALP = alkaline phosphatase;
HR = hazard ratio; LDH = lactate dehydrogenase; PSA = prostate specific antigen. CTC counts are from baseline
CTC enumeration.
3. Discussion
Our data confirms the strong prognostic value of CTCs in patients treated with cabazitaxel. We
found the CTC count to be independently associated with outcome in mCRPC patients who were
treated with cabazitaxel in the second line of chemotherapy, besides the well-known prognostic
parameters hemoglobin and alkaline phosphatase. To the best of our knowledge, this is the largest
study investigating the association between CTC numbers and outcome to cabazitaxel treatment.
Climent et al. have assessed baseline CTC numbers in 56 patients receiving cabazitaxel therapy. They
also found an association between CTC count and PFS, however they did not find a statistically
significant association between CTC count and OS [12].
Conversions between the favorable group (< 5 CTCs) and unfavorable group (≥ 5 CTCs) have been
described in mCRPC patients, however not yet in a large set of cabazitaxel treated patients. Literature
has shown for both metastatic breast and prostate cancer that patients who are in the favorable group
at baseline and follow-up have the best prognosis, while patients who are in the unfavorable group
at baseline and follow-up have the worst prognosis [8,16]. In these studies, mCRPC patients who
switched from ≥ 5 CTCs at baseline to < 5 CTCs at follow-up had a better prognosis than patients who
had < 5 CTCs at baseline but increased to ≥ 5 CTCs at follow-up. In the current study, we looked at
baseline CTC count and CTC count after six weeks of therapy instead of after therapy failure, which
was done in the previous described study [8]. We chose the six-week time point as our aim was to
detect early progression in our patients. This would allow patients to switch therapies in an early
stage of therapy. Our data showed that after dividing our patients into four groups depending on
CTC count before and during therapy, patients with an unfavorable CTC count at baseline and during
treatment indeed had the worst prognoses. However, the difference between the other 3 groups
was less clear. The relatively small sample size of these subgroups (especially group 3 (< 5 CTCs to
≥ 5 CTCs) contained only 5 patients) limits the power of this analysis, so based on our data no firm
conclusion can be drawn for CTC conversions during therapy. Preferably, this analysis should be
repeated with more patients and with CTC count assessed at progression of disease.
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In multivariable analysis for both PFS and OS, CTC count, alkaline phosphatase and hemoglobin
were independent prognostic factors. Hemoglobin and alkaline phosphatase are known prognostic
factors in mCRPC [17]. Patients with lower hemoglobin levels (< 12 g/dL) have shorter OS, while for
CTC count and alkaline phosphatase the relation is inversed. Alkaline phosphatase originates mainly
from bone and liver, with 40–50% coming from bone in adults [18]. Since 90% of the mCRPC patients
have radiologic evidence of bone metastasis [3], alkaline phosphatase is an important biomarker in
prostate cancer. For cabazitaxel, no direct effect on alkaline phosphatase is known, only indirect when
the tumor burden decreases, alkaline phosphatase levels also decrease [19]. Also for hemoglobin no
direct effect of cabazitaxel is known. Both alkaline phosphatase and hemoglobin can be influenced by
tumor burden, but also by a patient’s underlying condition. CTCs are the only factor that reflect the
tumor burden directly. However, all of these markers together can help physicians in deciding which
patients should receive cabazitaxel treatment at that moment.
In addition to traditional clinical parameters and CTC counts, we also assessed the clinical value
of a CTC derived gene expression profile to gain more insight into the biology of the tumors. Therefore,
91 genes with proven involvement in prostate cancer were measured in mRNA from the CTC enriched
samples. Of these genes, 34 genes had higher expression in the CTCs than in the leukocyte background
and were used for further analysis. Using these 34 genes to cluster the 63 samples for which baseline
gene expression data were available, the samples were clearly divided into two groups, which showed
a significant difference in CTC count. The cluster could be biased by CTC count, however, we do
observe clear variation in gene expression beyond sheer CTC count, indicating that the differences are
probably not just driven by numbers of CTCs.
The five genes from the gene expression signature with the highest discriminatory power to
predict PFS on cabazitaxel were AGR2, FOXA1, DKK1, FAT1 and TMPRSS2. All genes used for the
gene expression panel were selected based on expression and clinical relevance in prostate cancer.
Looking at these five genes, AGR2 is a CTC-specific gene in metastatic breast and colorectal cancer that
has been associated with poor outcome in prostate cancer patients [20–23]. FOXA1 is a key component
of the AR transcriptional complex and overexpression leads to enrichment of the PTEN and WNT
signaling pathway [24]. DKK1 is a WNT signaling inhibitor and has been associated with poor survival
in prostate cancer patients [25]. FAT1 is a tumor suppressor gene that affects the WNT signaling
pathway [26] and TMPRSS2 is an AR-regulated gene that is involved in a gene fusion (TMPRSS2-ERG)
in prostate cancer [27]. Prostate cancers with a positive TMPRSS2-ERG fusion show increased WNT
signaling [28]. In summary, these genes are especially involved in the AR and WNT signaling pathways.
While the role of the AR pathway has been well-established in prostate cancer, the role of the WNT
signaling pathway is less clear. However, changes in the WNT signaling pathway have been described
in prostate cancer, especially in the development of mCRPC. The genes presented here emphasize the
need to investigate the role of the WNT pathway in mCRPC and eventually look at the possibility of
using WNT modulators in mCRPC patients [29,30].
The gene expression signature of five genes to predict outcome on cabazitaxel therapy showed no
significant difference in PFS. Reviewing the Kaplan–Meier curve, a difference in the first 7 months
of treatment is visible. However, after that moment, the number of patients is too small to make
firm conclusions. For OS, there was a significant difference based on this 5-gene profile, however,
in multivariate analysis this was not an independent prognostic factor. Literature shows several
studies with gene expression profiles determined in peripheral blood [31–36] or on CTCs [37–43]
that are associated with outcome in patients with metastatic prostate cancer. Especially the studies
of Wang et al. [36], Olmos et al. [34], and Ross and al. [35], in which gene expression profiles were
established in whole blood of mCRPC patients, showed prognostic value of the established gene
profiles in an independent training and validation set. However, all of the studies mentioned above
still lack prospective validation. Also, none of these studies assessed a gene expression profile that
purely predicts response to cabazitaxel. Despite the lack of clinical value of the approach we described
here, we still feel that assessing the clinical value of gene expression profiles established in CTCs is
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worth pursuing. CTCs, as enumerated by the CellSearch system, which probably does not isolate
the CTCs with a more mesenchymal phenotype [44], do have strong prognostic power, as shown
here and in many other studies, and therefore represent a biologically relevant population of cells.
A limitation of CTC isolation with the CellSearch system is the background of leukocytes present
after enrichment of CTCs, however, there is less background present than after isolation of peripheral
blood mononuclear cells (PBMCs). This background severely limits the number of genes that can be
evaluated, since only genes can be evaluated that are solely expressed in CTCs and not in leukocytes.
Using techniques that enable the isolation of pure fractions of CTCs would increase the number of
genes that can be evaluated for prognostic and predictive relevance and also gives the opportunity to
assess heterogeneity between CTCs within one patient, and therefore deserves further study.
A limitation of this study was the number of patients that were available for analysis. For CTC
comparison analysis, 95 matched CTC samples were available. However, when dividing these patients
into different subgroups, some subgroups were too small to make firm conclusions. Also, for baseline
gene expression samples only 63 samples were available, of which almost all patients had ≥ 5 CTCs,
which made it difficult to make comparisons in this group. Furthermore, this group mostly contained
patients with worse prognoses based on their CTC count.
4. Materials and Methods
4.1. Patients
The mCRPC patients starting with a new line of cabazitaxel treatment were selected from a
prospective multicenter trial (CABARESC trial, NTR2991). In this study, mCRPC patients who
progressed after docetaxel treatment for CRPC were included and randomized to receive 25 mg/m2 of
cabazitaxel with or without budesonide treatment [45]. Treatment with cabazitaxel continued until
progression of disease or unacceptable toxicity with a maximum of ten cycles. The primary objective of
CABARESC was to evaluate the effects of budesonide on cabazitaxel-induced diarrhea [45]. As a side
study, blood was drawn for CTC enumeration and characterization in this trial. If a patient provided
consent to participate in this side study, blood was drawn before the start of cabazitaxel treatment
and before the third cycle of cabazitaxel. In total, 246 mCRPC patients were included, of whom 124
provided consent for CTC enumeration and characterization. Of these 124 patients, four patients were
excluded due to protocol violation (n = 2) and screen failure (n = 2). Therefore, a total of 120 patients
were available for this study (see Figure 3). The study was approved by the Erasmus MC and local
Institutional Review Boards (METC 11–324). All patients provided written informed consent. Clinical
data were collected from all patients.
4.2. CTC Enumeration and mRNA Isolation
For CTC enumeration 7.5 mL blood was collected in a CellSave tube and for characterization 7.5 mL
blood was collected in an EDTA tube before start and during cabazitaxel treatment. Blood was processed
with the CellSearch system (CellSearch enumeration kit and CellSearch profile kit, Menarini-Silicon
Biosystems, Huntington Valley, PA, USA). For enumeration, blood was processed within 96 hours,
while for characterization blood was processed within 24 h. After CTC enrichment, mRNA was isolated
with the AllPrep DNA/RNA Micro Kit (Qiagen, Germantown, MD, USA). Thereafter, cDNA was
generated, which was pre-amplified for the targets of interest and real time amplified (RT-qPCR) using
Taqman Gene Expression Assays (Applied Biosystems, Carlsbad, CA). For a more detailed description,
see previously published papers [22,46].
A baseline CTC sample was collected in 114 of the 120 patients. For six patients a baseline CellSave
tube was not drawn, and therefore CTCs could not be enumerated. For 100 patients a follow-up sample
was collected after six weeks. For the gene expression assays, material from 66 baseline samples and
59 follow-up samples was available. However, three baseline samples and ten follow-up samples were
excluded due to insufficient cDNA quality or quantity (see below). Therefore, 63 baseline samples
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and 49 follow-up samples were included for gene expression analysis, which contained 41 matched
samples (see Figure 3).
Figure 3. Patient inclusion. Flowchart of patient inclusion. In blue all patients who are included in
the CABARESC study and the side CTC enumeration study. In green the patients included for this
manuscript with available CTC enumeration. In Orange the patients included for this manuscript with
available gene expression data.
4.3. Sample Processing and Normalization
A gene expression profile of 147 genes was developed based on expression and clinical relevance
in prostate cancer, as derived from literature. Since a background of leukocytes remains after CTC
isolation with the CellSearch System, only genes with higher expression in prostate cancer than in
leukocytes were selected. Therefore, all genes were reviewed for expression in leukocytes and in
prostate cancer (SAGE Genie Database of the Cancer Genome Anatomy Project (http://cgap.nci.nih.gov/
SAGE/AnatomicViewer)). The 91 genes with the lowest leukocyte expression or highest upregulation
in prostate cancer (> 10×) were selected. Besides these 91 genes, three reference genes (GUSB, HMBS,
and HPRT1) were added to determine the quality of the sample, along with a negative control (H2O)
and a marker for leukocyte contamination (PTPRC, Protein Tyrosine Phosphatase Receptor type C).
Samples with an average reference gene signal of ∆Cq > 26.5 were considered to be of insufficient
cDNA quantity and/or quality, and were therefore excluded (n = 3).
For each of the 91 genes, the ∆Cq of 15 CellSearch enriched healthy blood donor (HBD) samples
was determined. A CTC sample was considered positive for a given gene if the Cq value was at least
one standard deviation higher (+1SD) than the mean ∆Cq of the 15 HBDs. If the expression of a gene
was below this cut-off, it was considered not detectable and given the value of the mean ∆Cq of the
15 HBDs.
To further correct for the leukocyte background and ensure the presence of a CTC-derived signal,
an epithelial profile was calculated for every sample. Previously, a 12-gene signal was identified that
was associated with epithelial tumor load in breast cancer patients [22]. The gene expression profile
used here for prostate cancer contained 6 of these 12 genes. Therefore, we correlated these 6 genes
(AGR2, FOXA1, EPCAM, IGFBP5, LAD1 and S100A16) from our prostate panel with the 12 genes
from the epithelial signal, which was measured in CTCs of 910 breast cancer patient samples and
20 HBD samples. For these 930 CTC samples, the ∆Cq sum of these 12 genes resulted in a cut-off of
−131 to identify the presence of at least one CTC in a sample. After correction for the slightly different
Cancers 2019, 11, 1212 11 of 14
HBD-corrected cut-off in this prostate cancer panel than in the breast cancer panel, the cut-off used
here based on the ∆Cq of six genes to identify a positive epithelial signal, and therefore presence of at
least one CTC, was −63.12 (see Supplementary Figure S4). Based on this epithelial cut-off, 10 samples
(1 baseline and 9 follow-up samples) were excluded for supposedly not containing any CTC-derived
signal. Therefore, a total of 63 baseline samples and 49 follow-up samples were available for comparison
of the gene expression profiles at baseline and after 6 weeks of therapy.
4.4. Statistical Analysis
Patient characteristics were compared between those with < 5 CTCs and those with ≥ 5 CTCs
by means of chi-square tests for categorical variables and the Mann–Whitney U test for continuous
variables. The cut off of 5 CTCs was chosen as this has been proven to be prognostic in patients with
mCRPC in several independent studies [8,47]. Progression free survival (PFS) was defined as time
between start of treatment and progression of disease, and overall survival (OS) was defined as time
from start of treatment until death by any cause. CTC count was determined both at baseline and
follow-up. Besides studying the effect of baseline CTC count as a marker for the survival outcomes,
the four possible groups of CTC count development (i.e., CTC count remaining smaller than 5 or ≥ 5,
CTC count increasing from < 5 to ≥ 5, or the other way around) were also studied. Furthermore, a
gene expression profile was developed and related to survival outcomes. For all these variables the
relation with PFS and OS was studied by means of log-rank tests and visualized with Kaplan–Meier
plots. Furthermore, univariate and multivariate Cox proportional hazards analyses were performed to
quantify the relationships further. For the multivariate analyses, a stepwise backward procedure was
followed including all available variables, and a threshold of p < 0.05 was applied for the selection of
variables to remain in the model.
In order to select the genes from the gene expression panel that were CTC-specific, we compared
expression levels per gene in the 112 patient CTC samples and in 15 HBD samples with the
Mann–Whitney U test. To correct for multiple testing, a FDR of 5% was applied. Gene expression data
of the 63 baseline samples were compared with the Survival Risk Prediction (SRP) tool from Biometric
Research Branch ArrayTools (BRB-ArrayTools, http://linus.nci.nih.gov/BRB-ArrayTools.html), using
a p-value of < 0.05. For hierarchical clustering, both the genes and the samples were normalized,
the genes were centered, and average uncentered clustering was performed using Cluster 3.0 and
visualized with Java Treeview version 1.6. All computations were performed using R (version 3.4.1)
and all reported p-values are two-sided (unless stated otherwise).
5. Conclusions
These data show that characterization of CTCs as of yet did not hold sufficient power to distinguish
outcome to cabazitaxel treatment. However, our data confirms the strong, independent prognostic
value of the CTCs for both PFS and OS in mCRPC patients that are treated with cabazitaxel in the
second line, together with alkaline phosphatase and hemoglobin.
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